Wanbury Limited
Regd. Office: BSEL Tech Park,
B-Wing, 10th Floor, Sector-30A,
Opp. Vashi Railway Station,
Vashi, Navi Mumbai 400703
Maharashtra, INDIA
Tel: +91-22-6794 2222
+91-22-7196 3222
CIN: L51900MH1988PLC048455
Email: info@wanbury.com
Website: www.wanbury.com

November 16, 2026

To BSE Limited PJ. Towers, Dalal Street Mumbai-400 001. **Scrip Code: 524212**	To National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. **SYMBOL: WANBURY**

Subject: Wanbury Limited's Tanuku Plant – US FDA Inspection – Updates

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under:

Further to our intimation dated 22nd July 2026 regarding the inspection by the United States Food and Drug Administration (US FDA) at one of the Company's Active Pharmaceutical Ingredient (API) manufacturing facilities situated at Tanuku, Andhra Pradesh, from 13 July 2026 to 17 July 2026, we hereby inform you that the Company has received communication from the US FDA that the inspection outcome has been classified as "Official Action Indicated" (OAI).

Based on the Company's current assessment, this inspection classification will not have any impact on business continuity or customer supplies of existing products from this facility.

The Company remains committed to work closely with the US FDA and maintaining the highest standards of quality, regulatory compliance and manufacturing practices across all its facilities and enhance its compliance on an ongoing basis.

We request you to take the above on record.

Thanking you.

Yours faithfully,
For Wanbury Limited

JITENDRA JAYANTILAL GANDHI
Digitally signed by JITENDRA JAYANTILAL GANDHI
Date: 2026.11.16 13:49:16 +05'30'

Jitendra J. Gandhi
Company Secretary